Abstract Immune checkpoint blockade (ICB) has transformed cancer therapy, yet clinical benefit remains highly heterogeneous. Although the intratumoral immune landscape is central to understanding ICB efficacy, peripheral T-cell clonal dynamics highlight the importance of immune processes beyond the tumor microenvironment.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Shengpeng
Contact Shengpeng, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack